Sonoma Pharmaceuticals' Q1 revenue rises 18%
Overview
Sonoma fiscal Q1 revenue rises 18% yr/yr, missing analyst expectations
U.S. revenue increases 57% due to higher health care product sales
Net loss per share for fiscal Q1 decreased 43% yr/yr
Result Drivers
U.S. REVENUE GROWTH - 57% increase in U.S. revenue driven by higher sales of human and animal health care products
STRATEGIC INITIATIVES - Expansion of consumer-focused product portfolio and regulatory approvals contributed to revenue growth
LATIN AMERICA DECLINE - Revenue decreased due to timing of customer orders for overflow manufacturing
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Miss | $4 mln | $4.05 mln (1 Analyst) |
Q1 Gross Profit |
| $1.50 mln |
|
Q1 Operating Expenses |
| $2.60 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79.6% above its August 6 closing price of $3.02
Press Release: ID:nACSglzl8a
